 |
Updated ACCP Clinical Practice Guidelines on Medical Therapy for Pulmonary Arterial Hypertension CME/CE Author Information and Disclosures Release Date: June 24, 2008; Valid for credit through June 24, 2009 | Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.5 nursing contact hours (0.25 contact hours are in the area of pharmacology) | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Summarize the most important changes in the recently updated ACCP Evidence-Based Clinical Practice Guidelines for Medical Therapy for Pulmonary Arterial Hypertension
- Identify factors other than New York Heart Association functional classification that clinicians
should consider when applying these guidelines in clinical practice
- Describe the role of combination therapy in the treatment of pulmonary arterial hypertension
Authors and Disclosures Steven D. Nathan, MD
Disclosure: Steven D. Nathan, MD, has disclosed that he has received grants for educational activities from
Actelion, Gilead, and United Therapeutics. Dr. Nathan has also disclosed that he has received grants for clinical research from Actelion and United Therapeutics, and that he has served as an advisor or consultant to Actelion, Gilead, and United Therapeutics. Vallerie V. McLaughlin, MD
Disclosure: Vallerie V. McLaughlin, MD, has disclosed that she has received grants for clinical research from Actelion, Gilead,
Pfizer, and United Therapeutics. Dr. McLaughlin has also disclosed that she has served as an advisor or consultant to Actelion, Gilead, and Pfizer. Adaani E. Frost, MD
Disclosure: Adaani E. Frost, MD, has disclosed that he has received grants for clinical research and educational activities from Gilead, Actelion, Pfizer, and United Therapeutics. Dr. Frost has also disclosed that he has served as an advisor or
consultant to Gilead, Actelion, Pfizer, and United Therapeutics, and has received honoraria for talks from Gilead, Actelion, and Pfizer. Susan Smith, RN, PhD
Disclosure: Susan Smith, RN, PhD, has disclosed no relevant financial relationships. Jennifer Brown, PhD
Disclosure: Jennifer Brown, PhD, has disclosed no relevant financial
relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
This Activity is sponsored by Medscape Continuing Education Provider Unit. Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology. Provider Number: 6FDKKC-PRV-05
Contact This Provider
|
|
